1. Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106
Primary Efficacy Endpoint of the DEFEAT-HF Trial There was no significant difference in the change in left ventricular end-systolic volume index (LVESVi) over 6 months between the spinal cord stimulation and control groups (p = 0.30). The bottom line of the box equals the 25th percentile, the top line equals the 75th percentile and the line within the box equals the median. The dots represent patient values that exceed the 75th percentile. Reproduced with permission from Zipes et al. (36). DEFEAT-HF = Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure.
Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106
The Authors